rosiglitazone has been researched along with Uterine Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carson, DD; Engel, BJ | 1 |
| Lan, SM; Li, CZ; Li, JF; Shi, M; Wang, F; Wang, YY; Wen, ZQ; Yang, GW; Zhang, CH; Zhang, H; Zhang, YJ; Zhu, Y | 1 |
2 other study(ies) available for rosiglitazone and Uterine Neoplasms
| Article | Year |
|---|---|
Activated EGFR stimulates MUC1 expression in human uterine and pancreatic cancer cell lines.
Topics: Blotting, Western; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression; Humans; Mucin-1; Pancreatic Neoplasms; Quinazolines; Rosiglitazone; Thiazolidinediones; Tyrphostins; Uterine Neoplasms | 2013 |
Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
Topics: Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Leiomyoma; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta3; Uterine Neoplasms | 2008 |